Tot Biopharm, a private equity-backed Chinese biopharmaceutical company, has filed for an initial public offering (IPO) in Hong Kong on Monday under the rules that allow pre-profit companies to float shares on the stock exchange.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access Over 11,000 stories and data posts over the past 8 years!Register Now
Already have an account or paid subscription?